Significant reductions in albuminuria are confirmed to correlate strongly with improved renal outcomes in diabetic patients, reinforcing its utility as a prognostic marker [39]
Conclusions and future directions The unexpectedly broad benefits of GLP-1 medicines now extend to reduction in rates of heart failure, stroke, myocardial infarction, diabetic kidney disease, metabolic liver disease, osteoarthritis peripheral vascular disease, and obstructive sleep apnea (Table 1
Medications like semaglutide and tirzepatide (known by commercial names like Ozempic, Wegovy, Zepbound and Mounjaro) that target GLP-1 receptors have revolutionized the treatment of diabetes and obesity, offering dramatic weight loss and surprising benefits for other chronic conditions
We describe molecular pathways and proteins, such as Wnt and calcitonin, that are associated with GLP-1 and bone tissue
A nonmedical prescription is something else entirely